What is the recommended management for an adult patient with minimal‑change disease?

Management of Adult Minimal Change Disease

High-dose oral glucocorticoids (prednisone 1 mg/kg/day, maximum 80 mg, or 2 mg/kg alternate-day, maximum 120 mg) are the first-line treatment for adult minimal change disease, administered for 4–16 weeks until complete remission, followed by a slow taper over 24 weeks total. 1

Diagnostic Confirmation

• Kidney biopsy is mandatory in all adults to confirm minimal change disease before initiating therapy, unlike in children where clinical diagnosis may suffice. 1
• Exclude secondary causes including malignancy, NSAID use, and systemic lupus erythematosus before attributing disease to primary MCD. 1

Initial Treatment: High-Dose Glucocorticoids

Dosing Regimen

• Prednisone 1 mg/kg/day (maximum 80 mg daily) or 2 mg/kg on alternate days (maximum 120 mg) is the standard initial regimen. 1, 2
• Daily oral dosing is most commonly used, but alternate-day dosing can be employed based on patient tolerance and side-effect profile. 1
• Intravenous steroids may be beneficial when bowel edema impairs oral absorption. 1

Treatment Duration

• Continue high-dose therapy for minimum 4 weeks and maximum 16 weeks before declaring treatment failure. 1
• Most adults achieve complete remission within 4–8 weeks, but some require the full 16-week course. 2, 3
• Never exceed 16 weeks of high-dose steroids without response, as toxicity outweighs any potential benefit. 1, 2

Tapering Protocol

• Begin tapering 2 weeks after achieving complete remission (defined as urine protein <200 mg/g or trace/negative dipstick for 3 consecutive days). 1, 2
• Reduce prednisone by 5 mg every 1–2 weeks until reaching physiologic replacement doses. 2, 4
• The total treatment course (high-dose plus taper) should span 6 months to minimize relapse risk. 2
• This represents a significant change from older 2012 guidelines that required 4 weeks minimum at high dose even after remission; the updated approach minimizes glucocorticoid toxicity. 1

Alternative First-Line Therapy: Calcineurin Inhibitors

Indications for CNI Instead of Steroids

Use calcineurin inhibitors as first-line therapy when glucocorticoids are contraindicated or pose unacceptable risk: 1, 2

• Uncontrolled diabetes mellitus
• Severe psychiatric disease
• Severe osteoporosis
• Morbid obesity

CNI Dosing and Monitoring

• Cyclosporine: 3–5 mg/kg/day divided twice daily, targeting trough levels of 100–175 ng/mL. 1, 2
• Tacrolimus: 0.05–0.1 mg/kg/day divided twice daily, targeting trough levels of 5–10 ng/mL. 1, 2
• Add low-dose prednisone (~0.15 mg/kg/day) when using CNI monotherapy to enhance efficacy. 1, 2
• Continue CNI therapy for at least 4–6 months before declaring treatment failure. 1, 2

CNI Safety Monitoring

• Monitor serum creatinine regularly; discontinue CNI if creatinine rises >30% above baseline and does not plateau after dose reduction. 1, 2, 5
• Consider repeat renal biopsy at 12–24 months if creatinine is rising or maintenance dose exceeds 3.5 mg/kg/day to assess for CNI-related nephrotoxicity. 1, 2, 5
• Both cyclosporine and tacrolimus carry risks of chronic kidney scarring with long-term use. 1

Management of Relapses

Infrequent Relapses (≤2 per year)

• Restart the same prednisone regimen that induced initial remission (1 mg/kg/day, maximum 80 mg) until proteinuria-free for at least 3 consecutive days. 1, 2, 5
• Then switch to 40 mg/m² on alternate days for minimum 4 weeks before tapering. 1, 2
• Relapse rates are high: 34–85% in adults and up to 71% in children. 1, 5, 3

Frequent Relapses or Steroid Dependence

Avoid repeated high-dose steroid courses due to cumulative toxicity; instead, employ steroid-sparing agents. 1, 2, 5

Steroid-Sparing Agents for Frequent Relapses

Treatment Options (in order of preference based on safety profile)

1. Rituximab: 375 mg/m² weekly for 4 doses 1, 2

   • Preferred for favorable safety profile and potential for sustained remission off immunosuppression. 6
   • Screen for hepatitis B surface antigen and latent tuberculosis (QuantiFERON) before administration. 1, 2
   • Patients treated with rituximab may be less likely to require therapy changes compared to other agents. 6

2. Calcineurin Inhibitors (Cyclosporine or Tacrolimus) 1, 2

   • Achieve complete remission in 73–82% of steroid-dependent adults. 1, 2, 5
   • Continue for ≥12 months before tapering to lowest effective dose. 1, 2
   • Tacrolimus monotherapy (without steroids) achieved 68% remission at 8 weeks and 88% at 26 weeks in a randomized trial, offering a steroid-free alternative. 7

3. Cyclophosphamide: 2–2.5 mg/kg/day for 8–12 weeks 1, 2

   • Achieves complete remission in ~51% and partial remission in additional ~23%. 1, 2
   • Achieves longer remissions in frequently relapsing patients compared to steroid-dependent patients. 5
   • Major limitation: cumulative gonadal toxicity and oncogenicity risk; reserve for patients who fail safer alternatives. 1, 5

4. Mycophenolate Mofetil 1, 2

   • Reserved for patients intolerant of steroids, cyclophosphamide, and CNIs. 1, 2, 5
   • Evidence quality is lower compared to other steroid-sparing agents. 1, 2

Steroid-Resistant Disease

Definition and Management

• Defined as failure to achieve remission after 8–16 weeks of adequate corticosteroid therapy. 1, 2
• Switch to CNI-based regimen rather than extending high-dose steroids beyond 16 weeks. 1, 2
• Perform repeat renal biopsy to confirm diagnosis and exclude focal segmental glomerulosclerosis, which may be clinically indistinguishable from MCD. 2, 5

Supportive Care During Active Nephrotic Syndrome

Edema Management

• Loop diuretic (furosemide) is first-line for severe edema. 1, 2
• Restrict dietary sodium to <2.0 g/day. 1, 2
• Avoid routine intravenous albumin; reserve only for clinical signs of hypovolemia (hypotension, tachycardia, poor perfusion). 1, 2

Infection Prevention

• Administer pneumococcal and annual influenza vaccines before or early in immunosuppressive therapy. 1, 2

Monitoring During Treatment

Active Treatment Phase

• Monitor urine protein daily using dipstick or spot urine protein-to-creatinine ratio. 1, 2
• Complete remission: urine protein <200 mg/g (<20 mg/mmol) or trace/negative dipstick for three consecutive days. 1, 2
• Check serum creatinine, estimated GFR, and serum potassium 2–4 weeks after therapy initiation. 1, 2

Post-Remission Surveillance

• Follow-up visits every 3–6 months for patients in sustained remission to detect early relapse. 1, 2, 5
• At each visit, measure serum creatinine, estimated GFR, and blood pressure. 1, 2, 5
• Extending monitoring intervals beyond 6 months may miss early relapses. 5

Long-Term Prognosis

• In glucocorticoid responders, long-term kidney survival is excellent: <5% progress to end-stage renal disease and 15-year patient survival is 83–98%. 1, 2, 5, 3
• Prognosis is less certain for patients who do not respond to glucocorticoids. 1
• Relapses occur more frequently in younger adults (<45 years) and typically within the first 6–12 months after remission. 3

Critical Pitfalls to Avoid

• Do not exceed 16 weeks of high-dose steroids without response; toxicity outweighs benefit. 1, 2
• Do not exceed 80 mg/day (or 120 mg alternate-day); higher doses do not improve response and markedly increase toxicity. 1, 2
• Do not declare steroid resistance before completing at least 8 weeks of adequate therapy. 1, 2
• Do not stop therapy prematurely when partial response is observed; continue up to 16 weeks. 1, 2
• Do not use statins solely for hyperlipidemia or ACE-I/ARB solely to lower proteinuria in normotensive patients during remission; current evidence does not support these interventions. 1, 2, 5
• Never abruptly stop glucocorticoids after prolonged supraphysiologic exposure (>2 weeks), as sudden withdrawal can precipitate adrenal crisis. 4